JP6774879B2 - セラミド及びｃｖｄ診断におけるその使用 - Google Patents

セラミド及びｃｖｄ診断におけるその使用 Download PDF

Info

Publication number
JP6774879B2
JP6774879B2 JP2016573763A JP2016573763A JP6774879B2 JP 6774879 B2 JP6774879 B2 JP 6774879B2 JP 2016573763 A JP2016573763 A JP 2016573763A JP 2016573763 A JP2016573763 A JP 2016573763A JP 6774879 B2 JP6774879 B2 JP 6774879B2
Authority
JP
Japan
Prior art keywords
ceramide
carbon atoms
alkyl chain
formula
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016573763A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519989A5 (enExample
JP2017519989A (ja
Inventor
レイヨ ラークソネン
レイヨ ラークソネン
Original Assignee
ゾラ バイオサイエンシーズ オサケ ユキチュア
ゾラ バイオサイエンシーズ オサケ ユキチュア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゾラ バイオサイエンシーズ オサケ ユキチュア, ゾラ バイオサイエンシーズ オサケ ユキチュア filed Critical ゾラ バイオサイエンシーズ オサケ ユキチュア
Publication of JP2017519989A publication Critical patent/JP2017519989A/ja
Publication of JP2017519989A5 publication Critical patent/JP2017519989A5/ja
Application granted granted Critical
Publication of JP6774879B2 publication Critical patent/JP6774879B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016573763A 2014-06-16 2015-06-16 セラミド及びｃｖｄ診断におけるその使用 Active JP6774879B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462012543P 2014-06-16 2014-06-16
US62/012,543 2014-06-16
US14/677,595 US9347960B2 (en) 2014-06-16 2015-04-02 Ceramides and their use in diagnosing CVD
US14/677,595 2015-04-02
PCT/EP2015/063492 WO2015193325A2 (en) 2014-06-16 2015-06-16 Ceramides and their use in diagnosing cvd

Publications (3)

Publication Number Publication Date
JP2017519989A JP2017519989A (ja) 2017-07-20
JP2017519989A5 JP2017519989A5 (enExample) 2018-07-26
JP6774879B2 true JP6774879B2 (ja) 2020-10-28

Family

ID=54835950

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016573763A Active JP6774879B2 (ja) 2014-06-16 2015-06-16 セラミド及びｃｖｄ診断におけるその使用

Country Status (10)

Country Link
US (5) US9347960B2 (enExample)
EP (2) EP3155440B1 (enExample)
JP (1) JP6774879B2 (enExample)
KR (3) KR102636885B1 (enExample)
CN (1) CN106461685B (enExample)
CA (1) CA2951578A1 (enExample)
MX (1) MX380642B (enExample)
SA (1) SA516380503B1 (enExample)
SG (1) SG11201609621RA (enExample)
WO (1) WO2015193325A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9347960B2 (en) * 2014-06-16 2016-05-24 Zora Biosciences, Oy Ceramides and their use in diagnosing CVD
US10996231B2 (en) * 2014-12-16 2021-05-04 Washington University Ceramides for evaluating risk of cardiovascular disease
US12313634B2 (en) * 2017-11-20 2025-05-27 Zora Biosciences Oy Methods for prediction and early detection of diabetes
CN114062581A (zh) * 2017-12-14 2022-02-18 江苏豪思生物科技有限公司 一种用于评估冠状动脉疾病的试剂盒
WO2020112149A1 (en) * 2018-12-01 2020-06-04 Binhai Industrial Technology Research Institute Of Zhejiang University Methods and compositions for the assessment of acute myocardial infarction (ami)
SG11202105172PA (en) * 2018-12-06 2021-06-29 Zora Biosciences Oy Biomarkers for cardiovascular events
CN112730638B (zh) * 2020-11-25 2022-07-29 首都医科大学附属北京朝阳医院 糖尿病合并心梗代谢标志物、检测试剂及试剂盒
CN112986454A (zh) * 2021-05-18 2021-06-18 天津云检医疗器械有限公司 急性心肌梗死的血清标志物、试剂盒和用途
CN113495160B (zh) * 2021-09-07 2021-11-19 宝枫生物科技（北京）有限公司 用于诊断高原环境下的缺血缺氧性脑病补充神经酸起效的分子标志物及其应用
WO2023108294A1 (en) * 2021-12-17 2023-06-22 National Research Council Of Canada Diagnostic lipid biomarkers for covid-19 and methods for use thereof
CN116500179B (zh) * 2023-04-21 2023-12-26 南京品生医疗科技有限公司 一种血浆中神经酰胺相关因子的原始得分计算及转换方法和系统
CN119198939B (zh) * 2024-08-30 2025-06-03 北京大学第三医院（北京大学第三临床医学院） 神经酰胺的检测试剂盒、应用检测试剂盒检测神经酰胺的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012018771A2 (pt) 2010-01-29 2017-06-20 Metanomics Gmbh ''método para dianosticar insuficência cardíaca em um sujeito''
DK2385374T4 (en) * 2010-05-05 2018-04-30 Zora Biosciences Oy LIPIDOMICS BIOMARKERS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE
EP3293522A3 (en) * 2010-06-20 2018-05-02 Zora Biosciences OY Lipidomic biomarkers for identification of high-risk coronary artery disease patients
US9541565B2 (en) 2011-04-08 2017-01-10 Zora Biosciences Oy Biomarkers for sensitive detection of statin-induced muscle toxicity
EP3527990A1 (en) 2011-07-28 2019-08-21 metanomics GmbH Use of sm_sphingomyelin (d18:1, c23:1) as a marker for heart failure
EP2592422A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
EP2592423A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
JP6389184B2 (ja) 2012-10-18 2018-09-12 メタノミクス ゲーエムベーハー サンプルにおいて代謝産物疾患バイオマーカーのクリアランス正規化量を決定するための手段及び方法
CN105008931A (zh) 2013-03-08 2015-10-28 佐拉生物科学公司 非高密度脂蛋白来源的cvd标志物
US9347960B2 (en) * 2014-06-16 2016-05-24 Zora Biosciences, Oy Ceramides and their use in diagnosing CVD

Also Published As

Publication number Publication date
CN106461685A (zh) 2017-02-22
EP3155440B1 (en) 2022-04-20
BR112016028534A2 (pt) 2017-08-22
US20240183866A1 (en) 2024-06-06
CA2951578A1 (en) 2015-12-23
US20160266152A1 (en) 2016-09-15
KR20240023696A (ko) 2024-02-22
KR102636885B1 (ko) 2024-02-19
US9347960B2 (en) 2016-05-24
WO2015193325A2 (en) 2015-12-23
US11940453B2 (en) 2024-03-26
CN106461685B (zh) 2021-05-25
US20220163547A1 (en) 2022-05-26
US20150362513A1 (en) 2015-12-17
KR102864779B1 (ko) 2025-09-25
MX380642B (es) 2025-03-12
EP3155440A2 (en) 2017-04-19
US20190113531A1 (en) 2019-04-18
SG11201609621RA (en) 2017-01-27
EP4089416A1 (en) 2022-11-16
MX2016016742A (es) 2017-04-27
US11474116B2 (en) 2022-10-18
SA516380503B1 (ar) 2023-03-23
WO2015193325A3 (en) 2016-02-25
KR20170018905A (ko) 2017-02-20
US10197582B2 (en) 2019-02-05
JP2017519989A (ja) 2017-07-20
KR20250139419A (ko) 2025-09-23

Similar Documents

Publication Publication Date Title
JP6774879B2 (ja) セラミド及びｃｖｄ診断におけるその使用
CN108445241B (zh) 用于鉴定高风险冠状动脉疾病患者的脂质组学标志
JP2014521928A (ja) アルツハイマー病のリスクの増加を診断するための方法
JP2025063061A (ja) 心血管イベントに対するバイオマーカー
US20190086386A1 (en) USE OF CERAMIDES AND LPLs IN DIAGNOSING CVD
HK40083140A (en) Ceramides and their use in diagnosing cardiovascular diseases
Ge et al. Circulating, imaging, and genetic biomarkers in cardiovascular risk prediction
HK1230721A1 (en) Ceramides and their use in diagnosing cvd
HK1230721B (en) Ceramides and their use in diagnosing cvd
KR102897948B1 (ko) 심혈관계 이벤트용 바이오마커
BR112016028534B1 (pt) Composição compreendendo ceramidas, kits e métodos in vitro para determinar o risco do desenvolvimento de doenças ou complicações cardiovasculares, avaliar e escolher tratamentos
Ricciardi Fibrillazione atriale nell’anziano: dalla valutazione clinica alle indagini dimetabolomica. Un approccio multidimensionale per lo studio di un’aritmia complessa. Atrial fibrillation in the elderly: From multidimensional assessment to a metabolomic insight. A complex approach for a complex arrhythmia.
US20240044826A1 (en) Metabolic vulnerability analyzed by nmr
Grau et al. Bringing Human Serum Lipidomics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180612

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200709

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200727

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201005

R150 Certificate of patent or registration of utility model

Ref document number: 6774879

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250